Sanofi’s inhalation contract manufacturing business acquired by Recipharm

Recipharm continues to grow with its acquisition of Sanofi’s inhalation contract manufacturing business in June of this year, together with the Holmes Chapel manufacturing facility in Cheshire which manufactures nasal sprays and metered dose inhalers. There are also a number of development suites for dry powder and other inhalation technologies. This manufacturing facility will be a welcome support to Recipharm’s Research Triangle Park in North Carolina which has its own inhalation development expertise.
CEO of Recipharm, Thomas Eldered, said: “Treatments for asthma and chronic obstructive pulmonary disease (COPD) are in high demand and are therefore key growth areas for our business. This new capability allows us to expand our offering to customers developing novel respiratory products by adding additional expertise and manufacturing capacity to Recipharm. We look forward to growing this side of our business and continuing to enhance our wider development services offering.”